ARTICLES|ONLINE FIRST Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis Jessica Widdifield, Jeffrey C Kwong, Simon Chen, et al Lancet Rheumatol Published:April 14, 2022 DOI:https://doi.org/10.1016/S2665-9913(22)00096-0 Summary Background We estimated COVID-19 vaccine effectiveness ag...

electronic Poor Outcome Screening (ePOS) Score The number of elderly and multimorbid patients admitted to the ICU continues to increase. These patients are at a high risk of dying and are likely to suffer from poor long-term outcomes such as functional and cognitive impairment, psychological distress and 6-month mortality. In addition, these patients have complex palliative care needs and could benefit from specialised palliative care consultation, which could redu...

CORRESPONDENCE Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron Gili Regev-Yochay, Tal Gonen, Mayan Gilboa, et al N Engl J Med March 16, 2022DOI: 10.1056/NEJMc2202542 TO THE EDITOR: In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months after the third dose in a series of three BNT162b2 doses (ClinicalTria...

ARTICLES|ONLINE FIRST Clinical features and management of human monkeypox: a retrospective observational study in the UK Hugh Adler, Susan Gould, Paul Hine, et al Lancet Infect Dis Published: May 24, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00228-6 Summary Background Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments...

ARTICLES| VOLUME 4, ISSUE 5, E351-E361, MAY 01, 2022 Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial MeiLan K Han, Martti Antila, Joachim H Ficker, et al Lancet Rheumatol 2022; 4: e351-e361 Summary Background COVID-19 is associated with acute respiratory distress and cytokine release syndrome. The Janus kin...

Editorials Acute hepatitis of unknown origin in children Muge Cevik, Angela L Rasmussen, Isaac I Bogoch, et al BMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o1197 (Published 17 May 2022)Cite this as: BMJ 2022;377:o1197 Many leads but few clear answers Recent reports of severe acute hepatitis of unknown aetiology in previously healthy children across multiple countries have resulted in health alerts and a race to identify the underlying cause. By 11 May,...

COMMENT|ONLINE FIRST When and which patients should receive remdesivir? Carolina Garcia-Vidal, Maurizio Sanguinetti Lancet Published: May 02, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00789-9 Despite 2 years having passed since the start of the COVID-19 pandemic, there is still intense debate about the best therapeutic strategy for patients with COVID-19. Multiple randomised studies have evaluated the efficacy of different antiviral,1, 2 anti-inflammat...

ARTICLES| VOLUME 4, ISSUE 5, E338-E350, MAY 01, 2022 Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al Lancet Rheumatol 2022; 4: e338-e350 Summary Background Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vaccination in patients with immune-me...

Awake Prone Positioning for Non-Intubated COVID-19 Patients Prone positioning can improve oxygenation and mortality for intubated patients with moderate to severe acute respiratory distress syndrome (ARDS). Prone positioning of non-intubated patients called awake prone positioning has been used for non-intubated patients with COVID-19 related acute hypoxaemic respiratory failure. It has been proven to improve oxygenation and potentially avoid intubation. Multiple s...

Original Investigation March 14, 2022 Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al JAMA. Published online March 14, 2022. doi:10.1001/jama.2022.2832 Key Points Question  Among patients at risk of disease progression, does early treatment of mild to moderate COVID-19 with the neutralizing an...